Evidence map›Paper›PMID 39470158›Full record

ArticleAnnals of clinical and translational neurology2024

FDG-PET patterns associate with survival in patients with prion disease.

Nick Corriveau-Lecavalier, Yoav D Piura, Brian S Appleby, Dror Shir, Leland R Barnard, Venkatsampath Gogineni, David T Jones, Gregory S Day

Abstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nick Corriveau-LecavalierDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-6561-9870
Yoav D PiuraDepartment of Neurology, Mayo Clinic in Florida, Jacksonville, Florida, USA.
Brian S ApplebyNational Prion Disease Pathology Surveillance Center, Case Western Reserve, Cleveland, Ohio, USA.
Dror ShirDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Leland R BarnardDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Venkatsampath GogineniDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
David T JonesDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Gregory S DayDepartment of Neurology, Mayo Clinic in Florida, Jacksonville, Florida, USA.ORCID 0000-0001-5133-5538

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI John Lucas · 2019 to 2026
$33.5M
Rapidly Progressive Dementia: Moving Beyond CJDK23AG064029 · NIA · WASHINGTON UNIVERSITY · PI DAY, GREGORY SCOTT · 2019 to 2023
$811k
Alzheimer's Disease Research Center P30AG62677-5CDC HHS NU38CK000486Consortium for Clarity in Alzheimer's Disease and Related Disorders Research Through ImagingEdson FoundationNIA NIH HHS K23 AG064029NIA NIH HHS P30 AG062677NIA NIH HHS U01 AG006786NIH HHS U01 AG06786
6 · The paper itself

Abstract

objectivePrion disease classically presents with rapidly progressive dementia, leading to death within months of diagnosis. Advances in diagnostic testing have improved recognition of patients with atypical presentations and protracted disease courses, raising key questions surrounding the relationship between patterns of neurodegeneration and survival. We assessed the contribution of fluorodeoxyglucose (FDG-PET) imaging for this purpose.

methodsFDG-PET were performed in 40 clinic patients with prion disease. FDG-PET images were projected onto latent factors generated in an external dataset to yield patient-specific eigenvalues. Eigenvalues were input into a clustering algorithm to generate data-driven clusters, which were compared by survival time.

resultsMedian age at FDG-PET was 65.3 years (range 23-85). Median time from FDG-PET to death was 3.7 months (range 0.3-19.0). Four data-driven clusters were generated, termed "Neocortical" (n = 7), "Transitional" (n = 12), "Temporo-parietal" (n = 13), and "Deep nuclei" (n = 6). Deep nuclei and transitional clusters had a shorter survival time than the neocortical cluster. Subsequent analyses suggested that this difference was driven by greater hypometabolism of deep nuclei relative to neocortical areas. FDG-PET-patterns were not associated with demographic (age and sex) or clinical (CSF total-tau, 14-3-3) variables.

interpretationGreater hypometabolism within deep nuclei relative to neocortical areas associated with more rapid decline in patients with prion disease and vice versa. FDG-PET informs large-scale network physiology and may inform the relationship between spreading pathology and survival in patients with prion disease. Future studies should consider whether FDG-PET may enrich multimodal prion disease prognostication models.

Indexed as

Fluorodeoxyglucose F18Positron-Emission TomographyPrion DiseasesAdultAgedAged, 80 and overBrainFemaleHumansMaleMiddle AgedYoung AdultFluorodeoxyglucose F18

Identifiers

PMID39470158
PMCPMC11651209

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.